<?xml version='1.0' encoding='utf-8'?>
<document id="27530188"><sentence text="Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine."><entity charOffset="0-8" id="DDI-PubMed.27530188.s1.e0" text="Edoxaban" /><entity charOffset="37-49" id="DDI-PubMed.27530188.s1.e1" text="ketoconazole" /><entity charOffset="51-63" id="DDI-PubMed.27530188.s1.e2" text="erythromycin" /><entity charOffset="69-81" id="DDI-PubMed.27530188.s1.e3" text="cyclosporine" /><pair ddi="false" e1="DDI-PubMed.27530188.s1.e0" e2="DDI-PubMed.27530188.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27530188.s1.e0" e2="DDI-PubMed.27530188.s1.e1" /><pair ddi="false" e1="DDI-PubMed.27530188.s1.e0" e2="DDI-PubMed.27530188.s1.e2" /><pair ddi="false" e1="DDI-PubMed.27530188.s1.e0" e2="DDI-PubMed.27530188.s1.e3" /><pair ddi="false" e1="DDI-PubMed.27530188.s1.e1" e2="DDI-PubMed.27530188.s1.e1" /><pair ddi="false" e1="DDI-PubMed.27530188.s1.e1" e2="DDI-PubMed.27530188.s1.e2" /><pair ddi="false" e1="DDI-PubMed.27530188.s1.e1" e2="DDI-PubMed.27530188.s1.e3" /><pair ddi="false" e1="DDI-PubMed.27530188.s1.e2" e2="DDI-PubMed.27530188.s1.e2" /><pair ddi="false" e1="DDI-PubMed.27530188.s1.e2" e2="DDI-PubMed.27530188.s1.e3" /></sentence><sentence text="Edoxaban, a novel factor Xa inhibitor, is a substrate of cytochrome P450 3 A4 (CYP3A4) and the efflux transporter P-glycoprotein (P-gp)"><entity charOffset="0-8" id="DDI-PubMed.27530188.s2.e0" text="Edoxaban" /></sentence><sentence text=" Three edoxaban drug-drug interaction studies examined the effects of P-gp inhibitors with varying degrees of CYP3A4 inhibition"><entity charOffset="7-15" id="DDI-PubMed.27530188.s3.e0" text="edoxaban" /></sentence><sentence text="" /><sentence text="In each study, healthy subjects received a single oral dose of 60 mg edoxaban with or without an oral dual P-gp/CYP3A4 inhibitor as follows: ketoconazole 400 mg once daily for 7 days, edoxaban on day 4; erythromycin 500 mg four times daily for 8 days, edoxaban on day 7; or single dose of cyclosporine 500 mg with edoxaban"><entity charOffset="69-77" id="DDI-PubMed.27530188.s5.e0" text="edoxaban" /><entity charOffset="141-153" id="DDI-PubMed.27530188.s5.e1" text="ketoconazole" /><entity charOffset="184-192" id="DDI-PubMed.27530188.s5.e2" text="edoxaban" /><entity charOffset="203-215" id="DDI-PubMed.27530188.s5.e3" text="erythromycin" /><entity charOffset="252-260" id="DDI-PubMed.27530188.s5.e4" text="edoxaban" /><entity charOffset="289-301" id="DDI-PubMed.27530188.s5.e5" text="cyclosporine" /><entity charOffset="314-322" id="DDI-PubMed.27530188.s5.e6" text="edoxaban" /><pair ddi="false" e1="DDI-PubMed.27530188.s5.e0" e2="DDI-PubMed.27530188.s5.e0" /><pair ddi="false" e1="DDI-PubMed.27530188.s5.e0" e2="DDI-PubMed.27530188.s5.e1" /><pair ddi="false" e1="DDI-PubMed.27530188.s5.e0" e2="DDI-PubMed.27530188.s5.e2" /><pair ddi="false" e1="DDI-PubMed.27530188.s5.e0" e2="DDI-PubMed.27530188.s5.e3" /><pair ddi="false" e1="DDI-PubMed.27530188.s5.e0" e2="DDI-PubMed.27530188.s5.e4" /><pair ddi="false" e1="DDI-PubMed.27530188.s5.e0" e2="DDI-PubMed.27530188.s5.e5" /><pair ddi="false" e1="DDI-PubMed.27530188.s5.e0" e2="DDI-PubMed.27530188.s5.e6" /><pair ddi="false" e1="DDI-PubMed.27530188.s5.e1" e2="DDI-PubMed.27530188.s5.e1" /><pair ddi="false" e1="DDI-PubMed.27530188.s5.e1" e2="DDI-PubMed.27530188.s5.e2" /><pair ddi="false" e1="DDI-PubMed.27530188.s5.e1" e2="DDI-PubMed.27530188.s5.e3" /><pair ddi="false" e1="DDI-PubMed.27530188.s5.e1" e2="DDI-PubMed.27530188.s5.e4" /><pair ddi="false" e1="DDI-PubMed.27530188.s5.e1" e2="DDI-PubMed.27530188.s5.e5" /><pair ddi="false" e1="DDI-PubMed.27530188.s5.e1" e2="DDI-PubMed.27530188.s5.e6" /><pair ddi="false" e1="DDI-PubMed.27530188.s5.e2" e2="DDI-PubMed.27530188.s5.e2" /><pair ddi="false" e1="DDI-PubMed.27530188.s5.e2" e2="DDI-PubMed.27530188.s5.e3" /><pair ddi="false" e1="DDI-PubMed.27530188.s5.e2" e2="DDI-PubMed.27530188.s5.e4" /><pair ddi="false" e1="DDI-PubMed.27530188.s5.e2" e2="DDI-PubMed.27530188.s5.e5" /><pair ddi="false" e1="DDI-PubMed.27530188.s5.e2" e2="DDI-PubMed.27530188.s5.e6" /><pair ddi="false" e1="DDI-PubMed.27530188.s5.e3" e2="DDI-PubMed.27530188.s5.e3" /><pair ddi="false" e1="DDI-PubMed.27530188.s5.e3" e2="DDI-PubMed.27530188.s5.e4" /><pair ddi="false" e1="DDI-PubMed.27530188.s5.e3" e2="DDI-PubMed.27530188.s5.e5" /><pair ddi="false" e1="DDI-PubMed.27530188.s5.e3" e2="DDI-PubMed.27530188.s5.e6" /><pair ddi="false" e1="DDI-PubMed.27530188.s5.e4" e2="DDI-PubMed.27530188.s5.e4" /><pair ddi="false" e1="DDI-PubMed.27530188.s5.e4" e2="DDI-PubMed.27530188.s5.e5" /><pair ddi="false" e1="DDI-PubMed.27530188.s5.e4" e2="DDI-PubMed.27530188.s5.e6" /><pair ddi="false" e1="DDI-PubMed.27530188.s5.e5" e2="DDI-PubMed.27530188.s5.e5" /><pair ddi="false" e1="DDI-PubMed.27530188.s5.e5" e2="DDI-PubMed.27530188.s5.e6" /></sentence><sentence text=" Serial plasma samples were obtained for pharmacokinetics and pharmacodynamics" /><sentence text=" Safety was assessed throughout the study" /><sentence text="" /><sentence text="Coadministration of ketoconazole, erythromycin, or cyclosporine increased edoxaban total exposure by 87%, 85%, and 73%, respectively, and the peak concentration by 89%, 68%, and 74%, respectively, compared with edoxaban alone"><entity charOffset="20-32" id="DDI-PubMed.27530188.s9.e0" text="ketoconazole" /><entity charOffset="34-46" id="DDI-PubMed.27530188.s9.e1" text="erythromycin" /><entity charOffset="51-63" id="DDI-PubMed.27530188.s9.e2" text="cyclosporine" /><entity charOffset="74-82" id="DDI-PubMed.27530188.s9.e3" text="edoxaban" /><entity charOffset="211-219" id="DDI-PubMed.27530188.s9.e4" text="edoxaban" /><pair ddi="false" e1="DDI-PubMed.27530188.s9.e0" e2="DDI-PubMed.27530188.s9.e0" /><pair ddi="false" e1="DDI-PubMed.27530188.s9.e0" e2="DDI-PubMed.27530188.s9.e1" /><pair ddi="false" e1="DDI-PubMed.27530188.s9.e0" e2="DDI-PubMed.27530188.s9.e2" /><pair ddi="false" e1="DDI-PubMed.27530188.s9.e0" e2="DDI-PubMed.27530188.s9.e3" /><pair ddi="false" e1="DDI-PubMed.27530188.s9.e0" e2="DDI-PubMed.27530188.s9.e4" /><pair ddi="false" e1="DDI-PubMed.27530188.s9.e1" e2="DDI-PubMed.27530188.s9.e1" /><pair ddi="false" e1="DDI-PubMed.27530188.s9.e1" e2="DDI-PubMed.27530188.s9.e2" /><pair ddi="false" e1="DDI-PubMed.27530188.s9.e1" e2="DDI-PubMed.27530188.s9.e3" /><pair ddi="false" e1="DDI-PubMed.27530188.s9.e1" e2="DDI-PubMed.27530188.s9.e4" /><pair ddi="false" e1="DDI-PubMed.27530188.s9.e2" e2="DDI-PubMed.27530188.s9.e2" /><pair ddi="false" e1="DDI-PubMed.27530188.s9.e2" e2="DDI-PubMed.27530188.s9.e3" /><pair ddi="false" e1="DDI-PubMed.27530188.s9.e2" e2="DDI-PubMed.27530188.s9.e4" /><pair ddi="false" e1="DDI-PubMed.27530188.s9.e3" e2="DDI-PubMed.27530188.s9.e3" /><pair ddi="false" e1="DDI-PubMed.27530188.s9.e3" e2="DDI-PubMed.27530188.s9.e4" /></sentence><sentence text=" The half-life did not change appreciably" /><sentence text=" Exposure of M4, the major active edoxaban metabolite, was consistent when edoxaban was administered alone or with ketoconazole and erythromycin"><entity charOffset="34-42" id="DDI-PubMed.27530188.s11.e0" text="edoxaban" /><entity charOffset="75-83" id="DDI-PubMed.27530188.s11.e1" text="edoxaban" /><entity charOffset="115-127" id="DDI-PubMed.27530188.s11.e2" text="ketoconazole" /><entity charOffset="132-144" id="DDI-PubMed.27530188.s11.e3" text="erythromycin" /><pair ddi="false" e1="DDI-PubMed.27530188.s11.e0" e2="DDI-PubMed.27530188.s11.e0" /><pair ddi="false" e1="DDI-PubMed.27530188.s11.e0" e2="DDI-PubMed.27530188.s11.e1" /><pair ddi="false" e1="DDI-PubMed.27530188.s11.e0" e2="DDI-PubMed.27530188.s11.e2" /><pair ddi="false" e1="DDI-PubMed.27530188.s11.e0" e2="DDI-PubMed.27530188.s11.e3" /><pair ddi="false" e1="DDI-PubMed.27530188.s11.e1" e2="DDI-PubMed.27530188.s11.e1" /><pair ddi="false" e1="DDI-PubMed.27530188.s11.e1" e2="DDI-PubMed.27530188.s11.e2" /><pair ddi="false" e1="DDI-PubMed.27530188.s11.e1" e2="DDI-PubMed.27530188.s11.e3" /><pair ddi="false" e1="DDI-PubMed.27530188.s11.e2" e2="DDI-PubMed.27530188.s11.e2" /><pair ddi="false" e1="DDI-PubMed.27530188.s11.e2" e2="DDI-PubMed.27530188.s11.e3" /></sentence><sentence text=" With cyclosporine, M4 total exposure increased by 6"><entity charOffset="6-18" id="DDI-PubMed.27530188.s12.e0" text="cyclosporine" /></sentence><sentence text="9-fold and peak exposure by 8" /><sentence text="7-fold, suggesting an additional interaction" /><sentence text=" Pharmacodynamic effects were reflective of increased edoxaban exposure"><entity charOffset="54-62" id="DDI-PubMed.27530188.s15.e0" text="edoxaban" /></sentence><sentence text=" No clinically significant adverse events were observed" /><sentence text="" /><sentence text="Administration of dual inhibitors of P-gp and CYP3A4 increased edoxaban exposure by less than two-fold"><entity charOffset="63-71" id="DDI-PubMed.27530188.s18.e0" text="edoxaban" /></sentence><sentence text=" This effect appears to be primarily due to inhibition of P-gp" /><sentence text=" The impact of CYP3A4 inhibition appears to be less pronounced, and its contribution to total clearance appears limited in healthy subjects" /><sentence text="" /></document>